Media
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
10 November 2026
Date
12 November 2026
The Access to Medicine Index 2026 has been released – Novartis is ranked 1st and GSK is ranked 2nd
In an article for Japanese media outlet, What to Noh, Taro Watanabe covers the release of the 2026 Access to Medicine Index, focusing on the performance of the Japanese pharmaceutical companies assessed in the report.
The article breaks down the Access to Medicine Index's geographic and disease scope, noting that it considers 113 low- and middle-income countries and 84 diseases, conditions and pathogens, as well as laying out how pharmaceutical companies are scored in the report.Â
Taro notes that all four Japanese companies assessed have seen their overall scores decline for the second consecutive time since the 2022 edition.Â
The article also includes a section on what the top companies are doing right – noting that patient reach is an important metric considered by the Index.Â